Swiss Medtech Firm Raises $7M for Biosensing
Xsensio SA, a Swiss company developing near real-time continuous biochemical monitoring, has closed an oversubscribed $7 million Series A funding round. The investment will accelerate the clinical deployment of its technology, which aims to provide continuous data on the body's chemistry.
The latest funding round was spearheaded by WI Harper, a venture capital firm with roots in San Francisco, and included participation from Privilège Ventures and the European Innovation Council. This syndicate of investors highlights a blend of US, European, and Asian capital, indicating broad international confidence in Xsensio's technology and market strategy. At the core of Xsensio's innovation is its "Lab-on-Skin" wearable biosensing platform. This technology utilizes a proprietary, highly miniaturized chip developed at the Swiss Federal Institute of Technology (EPFL) to track biochemical data like electrolytes, metabolites, and proteins directly from the skin's surface in real time. The company, founded in 2014 by CEO Esmeralda Megally and Karin Jaymes, has a history of securing strategic backing. Before this Series A, Xsensio had already raised approximately $4.55 million over 10 rounds and secured a collaboration agreement with the Mayo Clinic in February 2023 to advance its technology for critical care applications. To bolster its manufacturing and scalability, Xsensio has announced a long-term collaboration with semiconductor giant Texas Instruments. This partnership aims to leverage Texas Instruments' expertise in CMOS integration and miniaturization to ensure the reliable and cost-effective deployment of Xsensio's biosensing systems. Xsensio is entering a rapidly growing market for biochemical sensors, which is projected to expand from over $30 billion in 2025 to more than $51 billion by 2031. The primary drivers for this growth include the rising prevalence of chronic diseases and the increasing demand for point-of-care diagnostics and continuous health monitoring. The company's initial focus is on early detection of organ dysfunction in critical care, oncology, and post-surgical recovery settings. However, the technology has broader applications, including chronic disease management and monitoring athletic performance. The platform is designed to be modular, allowing adaptation for various clinical uses by tracking multiple biomarkers simultaneously.
